Welcome to our dedicated page for Lexaria Bioscien news (Ticker: LEXXW), a resource for investors and traders seeking the latest updates and insights on Lexaria Bioscien stock.
Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) regularly issues news updates that focus on the development and evaluation of its patented DehydraTECH™ oral drug delivery platform. Company press releases highlight progress in human and animal studies, capital raising activities, strategic partnerships, and expansion of its intellectual property portfolio. For followers of LEXXW, this news flow offers insight into how DehydraTECH is being tested and positioned within the pharmaceutical landscape.
A major theme in Lexaria’s recent news is its work with GLP‑1 drugs such as semaglutide, tirzepatide, and liraglutide. The company reports results from multiple human pilot studies and a Phase 1b study in Australia (GLP‑1‑H24‑4), where DehydraTECH‑processed oral formulations are compared against established injectable or oral products. These releases detail safety and tolerability outcomes, reductions in total and gastrointestinal adverse events, and comparative performance on measures like HbA1c, body weight, body composition, and pharmacokinetics.
News items also cover exploratory findings with DehydraTECH‑CBD, including reported blood pressure reductions in a clinical study arm, and pre-clinical work such as a fluorescently tagged semaglutide rodent biodistribution study. Beyond R&D, Lexaria’s announcements describe registered direct offerings on Nasdaq, concurrent warrant placements, and the intended use of proceeds to fund research, working capital, and general corporate purposes.
Additional updates include the extension of a Material Transfer Agreement with a pharmaceutical company to evaluate DehydraTECH, the engagement of a global life science business development advisory firm, and the issuance of new patents in areas such as diabetes, epilepsy, and antiviral treatments. Investors and observers monitoring LEXXW news can use these releases to track Lexaria’s clinical progress, partnering discussions, financing activities, and the evolution of its DehydraTECH-focused strategy over time.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) has announced promising results from its antiviral drug study, VIRAL-MC21-1, conducted by the National Research Council of Canada. The study confirms that DehydraTECH technology maintains the chemical stability of five tested antiviral drugs, supporting quicker regulatory approvals via the FDA's 505(b)(2) pathway. Key drugs include remdesivir and colchicine, which are associated with COVID-19 treatment. Lexaria plans to seek collaborations with pharmaceutical partners to enhance the application of DehydraTECH in antiviral therapies.
Lexaria Bioscience Corp. has been granted its first patent in Japan, strengthening its intellectual property portfolio, now totaling 20 patents globally. This patent focuses on stable, ready-to-drink beverage compositions containing lipophilic active agents. Lexaria's innovative DehydraTECH platform enhances the bio-absorption of non-psychoactive cannabinoids and NSAIDs, allowing for healthier ingestion methods. The company aims to expand its patent applications globally, targeting a market of nearly 4 billion people.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) has announced plans to voluntarily delist its common shares from the Canadian Securities Exchange (CSE) effective July 7, 2021. Starting July 8, 2021, trading will be consolidated on the Nasdaq Capital Markets, where the majority of trading has already occurred since its Nasdaq debut in January 2021. This decision aims to enhance shareholder liquidity and reduce operational costs, allowing the company to focus its resources on applied research and development programs. Lexaria's shares remain qualified investments for Canadian Registered Savings Plans.
Lexaria Bioscience Corp. held its 2021 Annual Meeting on June 28, with 2,735,413 shares represented, comprising 53.6% of its issued capital. Shareholders voted on several proposals, including the election of directors and the appointment of auditors. Key votes included 97.2% approval for Chris Bunka's directorship and 99.2% for auditor appointment. However, an amendment to the Equity Incentive Plan was only 68.3% approved. The company’s DehydraTECH technology continues to enhance drug delivery capabilities across various products, with a robust patent portfolio.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) reports promising results from its study VIRAL-A20-2, demonstrating that its DehydraTECH technology significantly enhances the oral bioavailability of remdesivir and ebastine. Findings indicate that drug levels in the bloodstream can be increased by up to three times compared to non-processed drugs. This improvement may increase the efficacy of these antiviral drugs against SARS-CoV-2. The study was conducted on male rats, with results showing significant improvements in drug delivery metrics.
Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) has provided a progress report on its 2021 applied R&D program, focusing on the enhanced drug delivery capabilities of its DehydraTECH technology. Significant studies include tolerability and pharmacokinetic evaluations for antiviral drugs and blood pressure testing using CBD. Key studies reported include VIRAL-A20-2 and VIRAL-A20-3 for antiviral drugs, and follow-up studies on blood pressure and NSAIDs. All studies are fully funded and aim to establish commercial partnerships.
Lexaria Bioscience Corp. has completed dosing in its first human clinical study, HYPER-H21-1, testing the efficacy of its DehydraTECH 2.0 CBD formulation for hypertension treatment. The study involved 24 participants aged 45 to 65, all of whom tolerated the treatment well with no serious adverse effects. Preliminary results are expected by July or August 2021, ahead of the previous Q3 timeline. The company is set to commence the second study, HYPER-H21-2, shortly, involving 16 participants and aiming for swift data analysis and reporting.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced that its DehydraTECH technology effectively inhibited the COVID-19 SARS-CoV-2 virus in an in vitro study using remdesivir and ebastine. The study's preliminary results confirmed the antiviral efficacy of these compounds, paving the way for future in vivo testing. The global antiviral market is projected to exceed USD $44 billion by 2026. Lexaria aims to enhance the oral delivery of these drugs, addressing key challenges in their bioavailability.
Lexaria Bioscience Corp. (NASDAQ: LEXX, LEXXW) announced remarkable results from its latest DehydraTECH 2.0 cannabidiol (CBD) formulation, achieving a 2,708% improvement in CBD absorption compared to the standard MCT control. This formulation outperformed previous versions, increasing efficacy by 174% over the original DehydraTECH 2.0. The ongoing HYPER-H21-1 human clinical hypertension study is expected to further validate these advancements. Lexaria's research, focused on enhancing drug delivery, positions it favorably in the burgeoning CBD market.
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) has announced its first patent grant in India, expanding its intellectual property portfolio to a total of 19 patents worldwide. This new patent, titled Stable ready-to-drink beverage compositions comprising lipophilic active agents, is valid for 20 years from December 1, 2016. The patent enhances Lexaria's existing protections in the EU, U.S., and Australia, allowing innovation in ready-to-drink beverages that include various active ingredients like NSAIDs and cannabinoids. Lexaria's patented technology, DehydraTECH™, improves the bio-absorption of these compounds.
FAQ
What is the current stock price of Lexaria Bioscien (LEXXW)?
